Valeant Pharmaceuticals International Inc. (NYSE:VRX) was up 5.3% during trading on Wednesday . The stock traded as high as $22.41 and last traded at $22.30, with a volume of 8,896,344 shares. The stock had previously closed at $21.17.

Several equities research analysts have commented on VRX shares. Rodman & Renshaw dropped their price target on shares of Valeant Pharmaceuticals International from $105.00 to $102.00 and set a “buy” rating on the stock in a research report on Tuesday, May 3rd. BMO Capital Markets reiterated a “market perform” rating and issued a $44.00 price target (down from $66.00) on shares of Valeant Pharmaceuticals International in a research report on Thursday, May 5th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $33.00 price target (down from $58.00) on shares of Valeant Pharmaceuticals International in a research report on Friday, June 3rd. TD Securities reiterated a “hold” rating and issued a $38.00 price target on shares of Valeant Pharmaceuticals International in a research report on Sunday, July 17th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating and issued a $35.00 price target (down from $50.00) on shares of Valeant Pharmaceuticals International in a research report on Wednesday, June 22nd. Seven equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $64.16.

The stock has a 50-day moving average of $22.18 and a 200-day moving average of $42.73. The company’s market capitalization is $7.55 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last released its earnings results on Tuesday, June 7th. The specialty pharmaceutical company reported $1.27 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.37 by $0.10. The business earned $2.37 billion during the quarter, compared to analyst estimates of $2.34 billion. During the same period in the prior year, the company earned $2.36 earnings per share. Valeant Pharmaceuticals International’s revenue was up 9.3% on a year-over-year basis. Equities research analysts anticipate that Valeant Pharmaceuticals International Inc. will post $6.55 EPS for the current fiscal year.

In related news, CEO Joseph C. Papa purchased 202,000 shares of the business’s stock in a transaction dated Friday, June 10th. The stock was purchased at an average cost of $24.48 per share, with a total value of $4,944,960.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,442,199 shares of the company’s stock, valued at $59,785,031.52. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Several institutional investors recently bought and sold shares of VRX. Nicholas Co. Inc. WI raised its position in Valeant Pharmaceuticals International by 15.6% in the fourth quarter. Nicholas Co. Inc. WI now owns 1,586,925 shares of the specialty pharmaceutical company’s stock worth $161,310,000 after buying an additional 214,435 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Valeant Pharmaceuticals International by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 79,777 shares of the specialty pharmaceutical company’s stock worth $8,110,000 after buying an additional 2,500 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in Valeant Pharmaceuticals International by 253.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 284,308 shares of the specialty pharmaceutical company’s stock worth $28,900,000 after buying an additional 203,760 shares during the last quarter. I.G. Investment Management LTD. raised its position in Valeant Pharmaceuticals International by 31.0% in the fourth quarter. I.G. Investment Management LTD. now owns 1,328,610 shares of the specialty pharmaceutical company’s stock worth $135,033,000 after buying an additional 314,616 shares during the last quarter. Finally, Diamond Hill Capital Management Inc. raised its position in Valeant Pharmaceuticals International by 77.8% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 301,374 shares of the specialty pharmaceutical company’s stock worth $30,635,000 after buying an additional 131,832 shares during the last quarter.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.